Travere Net Income From Continuing Ops from 2010 to 2024
| TVTX Stock | USD 18.25 0.01 0.05% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -376.3 M | Current Value -357.5 M | Quarterly Volatility 112.7 M |
Check Travere Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Travere Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 16.4 M, Selling General Administrative of 278.8 M or Other Operating Expenses of 548.1 M, as well as many indicators such as Price To Sales Ratio of 6.88, Dividend Yield of 0.0 or PTB Ratio of 3.16. Travere financial statements analysis is a perfect complement when working with Travere Therapeutics Valuation or Volatility modules.
Travere | Net Income From Continuing Ops |
Latest Travere Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Travere Therapeutics over the last few years. It is Travere Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Travere Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Travere Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (139,253,757) | |
| Coefficient Of Variation | (80.92) | |
| Mean Deviation | 89,701,041 | |
| Median | (59,731,000) | |
| Standard Deviation | 112,690,527 | |
| Sample Variance | 12699.2T | |
| Range | 316.6M | |
| R-Value | (0.87) | |
| Mean Square Error | 3437.6T | |
| R-Squared | 0.75 | |
| Significance | 0.000031 | |
| Slope | (21,802,655) | |
| Total Sum of Squares | 177788.2T |
Travere Net Income From Continuing Ops History
About Travere Therapeutics Financial Statements
Travere Therapeutics investors use historical fundamental indicators, such as Travere Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Travere Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -376.3 M | -357.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.